Kaye, Paul orcid.org/0000-0002-8796-4755, Matlashewski, Greg, Mohan, Sakshi et al. (4 more authors) (2023) Vaccine value profile for leishmaniasis. Vaccine. S153-S175. ISSN 0264-410X
Abstract
Leishmania infections are global, occurring in 98 countries and all World Health Organization (WHO) regions with 600 million to 1 billion people at risk of infection. Visceral leishmaniasis is associated with almost 20,000 reported deaths annually, with children under 5 years of age being at the greatest risk of mortality. Amongst WHO-recognised Neglected Tropical Diseases (NTDs), leishmaniasis is one of the most important in terms of mortality and morbidity. With an increasing global burden of disease and a growing threat from climate change, urbanisation and drug resistance, there remains an imperative to develop leishmaniasis vaccines. New tools to understand correlates of protection and to assess vaccine efficacy are being developed to ease the transition into larger scale efficacy trials or provide alternate routes to licensure. Early indications suggest a diverse portfolio of manufacturers exists in endemic countries with an appetite to develop leishmaniasis vaccines. This Vaccine Value Profile (VVP) provides a high-level, comprehensive assessment of the currently available data to inform the potential public health, economic, and societal value of leishmaniasis vaccines. The leishmaniasis VVP was developed by a working group of subject matter experts from academia, public health groups, policy organizations, and non-profit organizations. All contributors have extensive expertise on various elements of the leishmaniasis VVP and have collectively described the state of knowledge and identified the current gaps. The VVP was developed using only existing and publicly available information.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2023 The Authors. |
Dates: |
|
Institution: | The University of York |
Academic Units: | The University of York > Faculty of Social Sciences (York) > Centre for Health Economics (York) The University of York > Faculty of Sciences (York) > Hull York Medical School (York) |
Depositing User: | Pure (York) |
Date Deposited: | 10 Oct 2023 15:20 |
Last Modified: | 16 Oct 2024 19:30 |
Published Version: | https://doi.org/10.1016/j.vaccine.2023.01.057 |
Status: | Published |
Refereed: | Yes |
Identification Number: | 10.1016/j.vaccine.2023.01.057 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:204161 |
Download
Filename: 1_s2.0_S0264410X23000919_main.pdf
Description: Vaccine value profile for leishmaniasis
Licence: CC-BY 2.5